title: Ondansetron versus dolasetron: a comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures.
abstract: The purpose of this study was to determine if 4 mg of ondansetron and 12.5 mg of dolasetron were equally effective in preventing postoperative nausea and vomiting (PONV) in patients undergoing gynecological procedures. While the overall incidence of PONV appears to be 25% to 35%, the incidence among this patient population is considerably higher. Patients were assigned to 1 of 2 antiemetic treatment groups. Patients in group 1 received 4 mg of ondansetron at the end of surgery, while patients in group 2 received 12.5 mg of dolasetron at the end of surgery. Data collection occurred perioperatively and in the 24 hours following surgery. chi 2 determined there was no statistical difference between groups related to emesis in the postanesthesia care unit (PACU), emesis in the 24 hours following surgery, and side effects. Results of this study showed there was no statistically significant difference between 4 mg of ondansetron or 12.5 mg of dolasetron when administered at the end of surgery for preventing PONV in patients undergoing gynecological procedures. Given the cost difference between these 2 antiemetics, there is a potential for significant cost savings in this high-risk patient population.
authors.affiliation: Kaiser Permanente, Sacramento, Calif., USA.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Browning
authors.forename: Carol A
authors.initials: CA
authors.lastname: Fort
authors.forename: Kevan D
authors.initials: KD
authors.lastname: Kemp
authors.forename: Manardie F
authors.initials: MF
authors.lastname: Shimata
authors.forename: Melissa D
authors.initials: MD
authors.lastname: Strube
mesh_terms: D000932:Antiemetics / Q000191:economics / Q000627:therapeutic use*; D017046:Cost Savings; D004311:Double-Blind Method; D016527:Drug Costs / Q000706:statistics & numerical data; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007211:Indoles / Q000191:economics / Q000627:therapeutic use*; D017294:Ondansetron / Q000191:economics / Q000627:therapeutic use*; D020250:Postoperative Nausea and Vomiting / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D011446:Prospective Studies; D011807:Quinolizines / Q000191:economics / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000932:Antiemetics; D007211:Indoles; D011807:Quinolizines; D017294:Ondansetron; C060344:dolasetron